» Authors » Juan Ignacio Esteban

Juan Ignacio Esteban

Explore the profile of Juan Ignacio Esteban including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 59
Citations 809
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban J, Bes M, et al.
Hepatol Commun . 2021 Nov; 6(4):679-691. PMID: 34796691
Hepatocellular carcinoma (HCC), the sixth most common cancer worldwide, has an incidence rate equal to mortality. Over 80% of HCC cases occur within a high-risk population, mainly patients with both...
12.
Gregori J, Cortese M, Pinana M, Campos C, Garcia-Cehic D, Andres C, et al.
Emerg Microbes Infect . 2021 Aug; 10(1):1777-1789. PMID: 34402744
A common trait among RNA viruses is their high capability to acquire genetic variability due to viral and host mechanisms. Next-generation sequencing (NGS) analysis enables the deep study of the...
13.
Llorens-Revull M, Costafreda M, Rico A, Guerrero-Murillo M, Soria M, Piriz-Ruzo S, et al.
PLoS One . 2021 Jul; 16(7):e0254243. PMID: 34242330
Background & Aims: HCV CD4+ and CD8+ specific T cells responses are functionally impaired during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than 95% of treated...
14.
Garcia-Cehic D, Rando A, Rodriguez-Frias F, Gregori J, Costa J, Carrion J, et al.
J Viral Hepat . 2021 Mar; 28(9):1319-1324. PMID: 33720484
Direct-acting antivirals (DAAs) resolve chronic HCV infection in >95% of patients, but a small percentage do not respond to DAA-based therapy. These may be difficult to treat because of resistance-associated...
15.
Soria M, Garcia-Crespo C, Martinez-Gonzalez B, Vazquez-Sirvent L, Lobo-Vega R, de Avila A, et al.
J Clin Microbiol . 2020 Oct; 58(12). PMID: 32999010
Despite the high virological response rates achieved with current directly acting antiviral agents (DAAs) against hepatitis C virus (HCV), around 2% to 5% of treated patients do not achieve a...
16.
Andres C, Garcia-Cehic D, Gregori J, Pinana M, Rodriguez-Frias F, Guerrero-Murillo M, et al.
Emerg Microbes Infect . 2020 Aug; 9(1):1900-1911. PMID: 32752979
The SARS-CoV-2 spike (S) protein, the viral mediator for binding and entry into the host cell, has sparked great interest as a target for vaccine development and treatments with neutralizing...
17.
Chen Q, Perales C, Soria M, Garcia-Cehic D, Gregori J, Rodriguez-Frias F, et al.
Antiviral Res . 2019 Dec; 174:104694. PMID: 31857134
A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-based treatment regimens, often because of drug resistance-associated substitutions (RAS). The aim of this study was to characterize...
18.
Gallego I, Soria M, Garcia-Crespo C, Chen Q, Martinez-Barragan P, Khalfaoui S, et al.
J Virol . 2019 Dec; 94(6). PMID: 31852791
Previous studies documented that long-term hepatitis C virus (HCV) replication in human hepatoma Huh-7.5 cells resulted in viral fitness gain, expansion of the mutant spectrum, and several phenotypic alterations. In...
19.
Pons M, Rodriguez-Tajes S, Esteban J, Marino Z, Vargas V, Lens S, et al.
J Hepatol . 2019 Oct; 72(3):472-480. PMID: 31629779
Background & Aims: It is important to know which patients with hepatitis C are likely to develop liver-related complications after achieving a sustained virological response (SVR) to direct-acting antiviral (DAA)...
20.
Amer F, Yousif M, Hammad N, Garcia-Cehic D, Gregori J, Rando-Segura A, et al.
Infect Drug Resist . 2019 Oct; 12:2799-2807. PMID: 31571936
Purpose:  To study resistance-associated substitutions using next-generation sequencing in Egyptian hepatitis C virus-infected patients failing direct-acting antiviral treatment. Methods:  The current study describes three cases of treatment failure in patients...